| 2 -0.09 (-4.31%) | 04-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.41 | 1-year : | 4.2 |
| Resists | First : | 2.92 | Second : | 3.59 |
| Pivot price | 2.44 |
|||
| Supports | First : | 1.82 | Second : | 1.51 |
| MAs | MA(5) : | 2.05 |
MA(20) : | 2.63 |
| MA(100) : | 2.43 |
MA(250) : | 1.8  |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 12.7 |
D(3) : | 9.9 |
| RSI | RSI(14): 29.6 |
|||
| 52-week | High : | 3.65 | Low : | 0.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NMRA ] has closed above bottom band by 15.5%. Bollinger Bands are 36% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.11 - 2.12 | 2.12 - 2.13 |
| Low: | 1.96 - 1.97 | 1.97 - 1.98 |
| Close: | 1.98 - 2 | 2 - 2.02 |
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Wed, 01 Apr 2026
ARCH funds detail Neumora (NASDAQ: NMRA) ownership near 19% stake - Stock Titan
Tue, 31 Mar 2026
If You Invested $1,000 in Neumora Therapeutics Inc (NMRA) - Stock Titan
Tue, 31 Mar 2026
Neumora Therapeutics, Inc. Common Stock Q4 2025 Earnings Call Summary - Yahoo Finance
Mon, 30 Mar 2026
Neumora (NASDAQ: NMRA) maps key 2026–27 milestones for depression, Alzheimer’s and obesity drugs - Stock Titan
Thu, 19 Mar 2026
NMRA SEC Filings - Neumora Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Mon, 09 Mar 2026
Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 170 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 26.8 (%) |
| Held by Institutions | 62.3 (%) |
| Shares Short | 4,960 (K) |
| Shares Short P.Month | 6,050 (K) |
| EPS | -1.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.81 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -56.8 % |
| Return on Equity (ttm) | -104.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -209 (M) |
| Levered Free Cash Flow | -120 (M) |
| PE Ratio | -1.37 |
| PEG Ratio | 0 |
| Price to Book value | 2.43 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|